⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11159088 | 0.90 | ALDH1A1 (0.58) | — | |
| SCHEMBL21111119 | 0.80 | ALDH1A1 (1.00) | — | |
| SCHEMBL1997792 | 0.79 | — | — | |
| SCHEMBL21111146 | 0.75 | ALDH1A1 (0.79) | — | |
| SCHEMBL21111106 | 0.75 | ALDH1A1 (0.79) | — | |
| SCHEMBL29061272 | 0.73 | — | — | |
| SCHEMBL3643462 | 0.73 | — | — | |
| SCHEMBL28609350 | 0.71 | — | — | |
| SCHEMBL28611936 | 0.71 | — | — | |
| SCHEMBL2052713 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-6858216-B2 | Cosmetic agent containing 2-furanone derivatives | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-02-22 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| US-4405617-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-09-20 | — | — | US | disclosed |
| US-4385176-A | RING EXPANSION USING A LEWIS ACID | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-05-24 | — | — | US | disclosed |
| US-4308380-A | 2-Lower alkyl-2 or 3-cephem-4-carboxylic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-29 | — | — | US | disclosed |
| EP-0033965-A2 | New cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-08-19 | — | — | EP | disclosed |
| US-4203897-A | Penam derivatives | FUJISAWA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1980-05-20 | — | — | US | disclosed |
| US-4113940-A | ANTIMICROBIAL | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
| US-4091210-A | Preparation of 3-alkyl-3-cephem-4-carboxylic acid compounds from dithio isopropenyl azetidine carboxylic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-05-23 | — | — | US | disclosed |
| US-4084049-A | CEPHALOSPORIN ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-04-11 | — | — | US | disclosed |
| US-3984397-A | CYCLIZATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-10-05 | — | — | US | disclosed |
| US-3954732-A | BACTERICIDAL PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-05-04 | — | — | US | disclosed |